# Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

> **NCT04864821** · EARLY_PHASE1 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Osteosarcoma
- Neuroblastoma
- Gastric Cancer
- Lung Cancer

## Interventions

- **DRUG:** Targeting CD276 CAR T cells

## Key facts

- **NCT ID:** NCT04864821
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-14
- **Primary completion:** 2022-05-14
- **Final completion:** 2023-05-14
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04864821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04864821, "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04864821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*